Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 1/20 | 0.51 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.51 |
| ▸ | CHRNB4 | P30926 | 5/20 | 0.50 |
| ▸ | CHRNA3 | P32297 | 5/20 | 0.50 |
| ▸ | DCPS | Q96C86 | 4/20 | 0.48 |
| ▸ | DHFR | P00374 | 1/20 | 0.48 |
| ▸ | F2 | P00734 | 1/20 | 0.45 |
| ▸ | PLG | P00747 | 1/20 | 0.45 |
| ▸ | PLAU | P00749 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6015539 | 1.00 | CHRNB2 (0.51) | CHRNB2CHRNA4CHRNB4CHRNA3DCPS | |
| SCHEMBL6015541 | 0.81 | DCPS (0.59) | DCPSDHFR | |
| SCHEMBL12322040 | 0.80 | CHRNB2 (0.49) | CHRNB2CHRNA4CHRNB4CHRNA3F2 | |
| SCHEMBL12322038 | 0.80 | CHRNB2 (0.49) | CHRNB2CHRNA4CHRNB4CHRNA3F2 | |
| SCHEMBL6015552 | 0.79 | DCPS (0.54) | DCPSDHFRF2PLGPLAU | |
| SCHEMBL6015544 | 0.77 | DCPS (0.57) | DCPSDHFR | |
| SCHEMBL618000 | 0.77 | CHRNB2 (0.52) | CHRNB2CHRNA4CHRNB4CHRNA3F2 | |
| SCHEMBL10257173 | 0.77 | CHRNB2 (0.52) | CHRNB2CHRNA4CHRNB4CHRNA3F2 | |
| SCHEMBL10257366 | 0.77 | CHRNB2 (0.52) | CHRNB2CHRNA4CHRNB4CHRNA3F2 | |
| SCHEMBL6015535 | 0.77 | DCPS (0.54) | DCPSDHFRF2PLGPLAU |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012054526-A2 | CHEMOSENSORY RECEPTOR LIGAND-BASED THERAPIES | ELCELYX THERAPEUTICS, INC. (US) | 2012-04-26 | — | — | WO | disclosed |